<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952822</url>
  </required_header>
  <id_info>
    <org_study_id>060702</org_study_id>
    <nct_id>NCT00952822</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection</brief_title>
  <official_title>A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics and safety of Antihemophilic
      factor, recombinant, manufactured protein-free (rAHF-PFM) reconstituted in 2 mL sterile water
      for injection (SWFI) and compare with those of rAHF-PFM reconstituted in 5 mL of SWFI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted in Vivo Incremental Recovery</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
    <description>Increase in factor VIII concentration from pre- to post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-Adjusted Clearance</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as the weight-adjusted dose divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted clearance * mean residence time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Maximal factor VIII concentration post-infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Severity of Infusion Site Reactions</measure>
    <time_frame>Within 5 minutes pre-infusion up to 24 hours post-infusion</time_frame>
    <description>Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion Site Pain</measure>
    <time_frame>Within 5 minutes post-infusion up to 24 hours post-infusion</time_frame>
    <description>Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVATE reconstituted in 2 mL sterile water for infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADVATE reconstituted in 5 mL sterile water for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)</intervention_name>
    <description>Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ADVATE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject or subject's legally authorized representative has provided written
             informed consent

          -  The subject has severe hemophilia A as defined by a baseline FVIII activity &lt;= 1% of
             normal; tested at screening

          -  The adolescent/adult subject has a documented history of at least 150 exposure days to
             FVIII concentrates (either plasma-derived or recombinant), and the pediatric subject
             has at least 50 exposure days

          -  The subject is &gt;= 12 to &lt;= 65 years of age for the complete pharmacokinetic assessment
             and &gt;= 2 to &lt; 12 years for the incremental recovery assessment The subject has a
             Karnofsky performance score &gt; 60

          -  The subject is human immunodeficiency virus negative (HIV-) or HIV+ with stable CD4
             count &gt;= 200 cells/mm³ (CD4 count determined at screening, if necessary)

        Exclusion Criteria:

          -  The subject has a known hypersensitivity to mouse or hamster proteins or to FVIII
             concentrates

          -  The subject has a history of FVIII inhibitors with titer &gt;= 0. 5 BU (Bethesda Assay)
             or &gt;= 0.4 BU (Nijmegen modification of the Bethesda Assay) any time prior to screening

          -  The subject has a detectable FVIII inhibitor at screening, &gt;= 0.4 BU (Nijmegen
             modification of the Bethesda Assay), in the central laboratory

          -  The subject has severe chronic liver disease as evidenced by, but not limited to, any
             of the following: International Normalized Ratio (INR) &gt; 1.4, hypoalbuminemia, portal
             vein hypertension including presence of otherwise unexplained splenomegaly and history
             of esophageal varices

          -  The subject has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (e.g. qualitative platelet defect or Von Willebrand Disease)

          -  The subject has received another investigational product within 30 days of enrollment

          -  The subject's clinical condition may require major or moderate surgery (estimated
             blood loss &gt; 500 mL) during the period of participation in the study

          -  Subjects with clinically significant medical, psychiatric, or cognitive illness, or
             recreational drug/alcohol use that, in the opinion of the investigator, would affect
             subject safety or compliance

          -  The subject is a female of childbearing potential with a positive pregnancy test at
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wing-Yen Wong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>October 28, 2010</results_first_submitted>
  <results_first_submitted_qc>June 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2011</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted in the United States at 11 sites. Two cohorts were recruited (adolescent/adults aged ≥12 to ≤65 years and pediatrics aged ≥2 to &lt;12 years).</recruitment_details>
      <pre_assignment_details>Subjects meeting inclusion criteria were randomly assigned to receive a single sequence of 2 pharmacokinetic (PK) infusions of rAHF-PFM: reconstituted in 2mL then 5mL sterile water for injection (SWFI) or vice versa. Before each PK evaluation ≥3 day washout and negative factor VIII inhibitor titer was required. Ten subjects were screen failures</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adolescents/Adults - 2 mL Then 5 mL</title>
          <description>Adolescents/Adults - 2 mL then 5 mL: Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI for the 1st Pharmacokinetic (PK) Evaluation, then rAHF-PFM reconstituted in 5 mL SWFI for the 2nd PK Evaluation.</description>
        </group>
        <group group_id="P2">
          <title>Adolescents/Adults - 5 mL Then 2 mL</title>
          <description>Adolescents/Adults - 5 mL then 2 mL: Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI for the 1st Pharmacokinetic (PK) Evaluation, then rAHF-PFM reconstituted in 2 mL SWFI for the 2nd PK Evaluation.</description>
        </group>
        <group group_id="P3">
          <title>Pediatrics - 2 mL Then 5 mL</title>
          <description>Pediatrics - 2 mL then 5 mL: Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 2 mL SWFI for the 1st Pharmacokinetic (PK) Evaluation, then rAHF-PFM reconstituted in 5 mL SWFI for the 2nd PK Evaluation.</description>
        </group>
        <group group_id="P4">
          <title>Pediatrics - 5 mL Then 2 mL</title>
          <description>Pediatrics - 5 mL then 2 mL: Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 5 mL SWFI for the 1st Pharmacokinetic (PK) Evaluation, then rAHF-PFM reconstituted in 2 mL SWFI for the 2nd PK Evaluation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1st Pharmacokinetic Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>2nd Pharmacokinetic Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated Participants</title>
          <description>Participants who received at least 1 infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥2 to &lt;12 years (Number Pediatrics)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥12 to &lt;16 years (Number Adolescents)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥16 to 65 years (Number Adults)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Pediatrics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents/Adults</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve</title>
        <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Number of complete crossover participants (per protocol) who received the assigned sequence of 2 infusions: reconstituted in 2mL then 5mL SWFI or in 5mL then 2mL SWFI.</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve</title>
          <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
          <population>Number of complete crossover participants (per protocol) who received the assigned sequence of 2 infusions: reconstituted in 2mL then 5mL SWFI or in 5mL then 2mL SWFI.</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1257.20" spread="380.60"/>
                    <measurement group_id="O2" value="1297.42" spread="487.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence limits of -0.223 to 0.223 in accordance with FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence; 2001.</non_inferiority_desc>
            <param_type>Difference of Least-Squares Means</param_type>
            <param_value>-0.052</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.117</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Curve</title>
        <description>Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Number of complete crossover participants (intent to treat) who received the assigned sequence of 2 infusions: reconstituted in 2mL then 5mL SWFI or in 5mL then 2mL SWFI.</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve</title>
          <description>Total AUC when the concentration is extrapolated to zero using the slope of the β-phase of the model</description>
          <population>Number of complete crossover participants (intent to treat) who received the assigned sequence of 2 infusions: reconstituted in 2mL then 5mL SWFI or in 5mL then 2mL SWFI.</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1357.60" spread="436.24"/>
                    <measurement group_id="O2" value="1368.12" spread="553.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence limits of -0.223 to 0.223 in accordance with FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence; 2001.</non_inferiority_desc>
            <param_type>Difference of Least-Squares Means</param_type>
            <param_value>-0.016</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-0.076</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted in Vivo Incremental Recovery</title>
        <description>Increase in factor VIII concentration from pre- to post-infusion</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
          <group group_id="O3">
            <title>Pediatrics - 2 mL</title>
            <description>Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O4">
            <title>Pediatrics - 5 mL</title>
            <description>Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted in Vivo Incremental Recovery</title>
          <description>Increase in factor VIII concentration from pre- to post-infusion</description>
          <population>Intent to Treat</population>
          <units>IU/dL:IU/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.34"/>
                    <measurement group_id="O2" value="1.88" spread="0.40"/>
                    <measurement group_id="O3" value="1.33" spread="0.36"/>
                    <measurement group_id="O4" value="1.66" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
          <population>Per Protocol</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.54" spread="3.80"/>
                    <measurement group_id="O2" value="12.50" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-Adjusted Clearance</title>
        <description>Computed as the weight-adjusted dose divided by total AUC</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-Adjusted Clearance</title>
          <description>Computed as the weight-adjusted dose divided by total AUC</description>
          <population>Per Protocol</population>
          <units>mL/(kg*h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="0.95"/>
                    <measurement group_id="O2" value="3.81" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time</title>
        <description>Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time</title>
          <description>Computed as total area under the moment curve divided by the total AUC. Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
          <population>Per Protocol</population>
          <units>hours (h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.79" spread="5.24"/>
                    <measurement group_id="O2" value="14.34" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State</title>
        <description>Computed as weight-adjusted clearance * mean residence time</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State</title>
          <description>Computed as weight-adjusted clearance * mean residence time</description>
          <population>Per Protocol</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.13"/>
                    <measurement group_id="O2" value="0.51" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration</title>
        <description>Maximal factor VIII concentration post-infusion</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration</title>
          <description>Maximal factor VIII concentration post-infusion</description>
          <population>Per Protocol</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.77" spread="19.35"/>
                    <measurement group_id="O2" value="106.46" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Severity of Infusion Site Reactions</title>
        <description>Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).</description>
        <time_frame>Within 5 minutes pre-infusion up to 24 hours post-infusion</time_frame>
        <population>Participants who received at least 1 infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
          <group group_id="O3">
            <title>Pediatrics - 2 mL</title>
            <description>Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O4">
            <title>Pediatrics - 5 mL</title>
            <description>Participants aged ≥2 to &lt;12 years who received rAHF-PFM reconstituted in 5 mL SWFI</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Severity of Infusion Site Reactions</title>
          <description>Infusion-related local reactions (including pain, tenderness, erythema, induration, and bruising) and severity were evaluated according to an FDA-defined grading scale (FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007).</description>
          <population>Participants who received at least 1 infusion</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain- Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain- Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain- Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain- Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema- Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema- Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema- Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema- Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration- Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration- Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration- Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration- Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising- Mild (Grade 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising- Moderate (Grade 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising- Severe (Grade 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising- Potentially Life Threatening (Grade 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infusion Site Pain</title>
        <description>Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).</description>
        <time_frame>Within 5 minutes post-infusion up to 24 hours post-infusion</time_frame>
        <population>Participants who received at least 1 infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Adolescents/Adults - 2 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 2 mL SWFI</description>
          </group>
          <group group_id="O2">
            <title>Adolescents/Adults - 5 mL</title>
            <description>Participants aged ≥12 to ≤65 years who received rAHF-PFM reconstituted in 5 mL SWFI (note: 24 hours after infusion n=26)</description>
          </group>
          <group group_id="O3">
            <title>Pediatrics at Least 5 Years of Age - 2 mL</title>
            <description>Participants aged ≥5 years to &lt;12 years who received rAHF-PFM reconstituted in 2 mL SWFI (note: 6 hours after infusion n=7)</description>
          </group>
          <group group_id="O4">
            <title>Pediatrics at Least 5 Years of Age - 5 mL</title>
            <description>Participants aged ≥5 years to &lt;12 years who received rAHF-PFM reconstituted in 5 mL SWFI (note: 24 hours after infusion n=7)</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Site Pain</title>
          <description>Pain was assessed by participants (≥5 years of age) on a visual analog scale (VAS) from 0 (no pain) to 100 (worst possible pain).</description>
          <population>Participants who received at least 1 infusion</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 5 minutes (immediately) after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O3" value="8" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O4" value="4" lower_limit="0" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 ± 5 minutes after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0" upper_limit="66"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours ± 30 minutes after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During course of study</time_frame>
      <desc>AEs were collected by the investigators at study visits, and may result from laboratory and vital sign assessments collected or measured at the study visits</desc>
      <group_list>
        <group group_id="E1">
          <title>Adolescents/Adults</title>
          <description>Participants aged ≥12 to ≤65 years who received at least one infusion</description>
        </group>
        <group group_id="E2">
          <title>Pediatrics</title>
          <description>Participants aged ≥12 to ≤65 years who received at least one infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hemorrhage</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hemarthrosis</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint range of motion</sub_title>
                <description>Not related to study drug</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) up to 90 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wing-Yen Wong, MD, Global Sr Medical Dir Hemophilia</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>wing_yen_wong@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

